Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial

Ridolfi, Laura; Bertetto, Oscar; Santo, Antonio; Naglieri, Emanuele; Lopez, Massimo; Recchia, F.; Lissoni, Paolo; Galliano, Marco; Testore, Franco; Porta, Camillo; Maglie, M.; Dall’Agata, Monia; Fumagalli, Luca; Ridolfi, Ruggero

doi:10.3892/ijo.2011.1099

Cited by 25 publications

(32 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Information of 43 ASCO abstracts were collected by their clinical trial numbers through Clinicaltrials.gov or Google Scholar. Finally, we included 20 clinical trials1720212227282930313233343536373839404142, 17 from database search and 3313538 from ASCO abstracts (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

“…Survival data were extracted from all eligible trials. HRs of overall survival (OS) were reported directly in sixteen trials, but were estimated by median survival time of treatment group and control group for three trials274042. The remaining one trial only provided survival curve41, so HR was calculated through curve data.…”

Section: Resultsmentioning

confidence: 99%

“…Tumor-induced immunosuppressive phenomena were reversible in vitro by the addition of exogenous IL-240. A phase III randomized multicenter trial40 comparing chemotherapy with or without low dose IL-2 in patients with advanced NSCLC failed to demonstrate any survival benefits of IL-2. In this study, more patients experienced grade 4 AEs in chemotherapy plus IL-2 group than chemotherapy alone group (50 vs. 27).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis

Zhou

Wang

Deng

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Immunotherapy is a novel treatment for advanced non-small cell lung cancer (NSCLC) patients. Immunotherapy includes two main broad classes of therapeutic vaccines and immune checkpoint inhibitors, as well as cytokines, biological response modifiers and cellular therapy. The present systematic review and meta-analysis aims to evaluate the efficacy and safety of different classes of immunotherapy in patients with advanced NSCLC. Literature search was done on Medline, Embase and Cochrane Library. The primary endpoints were overall survival (OS) and grade ≥3 adverse events. Twenty randomized controlled trials were finally identified in our study. Efficacy analysis indicated an improvement of OS in advanced NSCLC patients after treating by therapeutic vaccines and immune checkpoint inhibitors, but not for other immunomodulators. Safety analysis showed that immunotherapy was well-tolerated. All kinds of grade ≥3 adverse events were similar between experimental group and control group except that neutropenia and thrombocytopenia had a higher incidence in patients received vaccines. In conclusion, immunotherapy is a promising treatment for advanced NSCLC patients. Our findings will be further confirmed and supplemented by several phase II and phase III RCTs which are going to complete in near future.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis

Zhou

Wang

Deng

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…A subsequent phase II trial by Correale et al showed that the addition of IL-2 to chemotherapy (gemcitabine plus docetaxel) in patients with advanced NSCLC improved response rates (58.3% vs. 28.6%) with good tolerability (10). However, these findings were not replicated in a phase III randomized trial of IL-2 in combination with chemotherapy with a cisplatin doublet (11). These results were further challenged by a subsequent study reporting a 20% partial response and 50% stable disease among 20 advanced NSCLC patients when IL-2 was administered with the pineal neuro-hormone melatonin (12).…”

Section: Cytokinesmentioning

confidence: 65%

Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting

2016

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide.In recent years, through a better understanding of the interactions between the immune system and tumor cells (TC), immunotherapy has emerged as a promising therapeutic strategy. Chemotherapy has long been reported to interfere with the immune response to the tumor and conversely, anti-tumor immunity may add to those effects.Anti-tumor vaccines, such as MAGE-A3, Tecetomide, TG4010, CIMAvax, tumor cell vaccines and dendritic cell (DC) vaccines emerged as potent inducers of the immune response against the tumor. More recently the approval of the anti-programmed cell death 1 (anti-PD-1) monoclonal antibodies nivolumab and pembrolizumab for previously treated advanced squamous and non-squamous NSCLC, as well as other immune checkpoint inhibitors delivering promising results, has radically transformed the therapeutic landscape of NSCLC. Combination strategies now appear as the next step. Notwithstanding these successes, immunotherapy still holds significant drawbacks and currently several improvements are needed before routine use in clinical practice, including identification of robust biomarkers for optimal patient selection, as well as defining the best way to evaluate response.

show abstract

“…Významnou limitaci léčeb-ného využití cytokinů v protinádorové léčbě představuje relativně vysoká toxicita a nevýhodná farmakokinetika [2][3][4][5][6][7]. V léčbě plicního karcinomu byly nejčas-těji zkoumány interleukin 2 a interferon α a γ. Přestože ně kte ré cytokiny byly hodnoceny v klinických studiích fáze II a III, jejich přínos nebyl potvrzen, a tak nenalezly významnějšího uplatnění v léčbě NSCLC ani v léčbě SCLC [11][12][13][14][15].…”

Section: Cytokinyunclassified

Immunotherapy in the Treatment of Lung Cancer

Fiala¹,

Šorejs²,

Pešek³

et al. 2017

Klin Onkol

View full text Add to dashboard Cite

1 Onkologická a radioterapeutická klinika LF UK a FN Plzeň 2 Biomedicínské centrum LF UK v Plzni 3 Klinika pneumologie a ftizeologie LF UK a FN Plzeň Souhrn Východiska: Karcinom plic zaujímá přední místa v incidenci i mortalitě nádorových onemocnění celosvětově, i v České republice. Přes významné pokroky v systémové onkologické léčbě dosažené v poslední době patří plicní karcinom mezi zhoubné nádory s nejhorší prognózou a potřeba hledání inovativních terapeutických prostředků a metod je zde stále velmi vysoká. Imunoterapie představuje dynamicky se rozvíjející oblast systémové onkologické léčby, která se v poslední době začíná významně uplatňovat i u pa cientů s plicním karcinomem. Nejlépe využitelný typ imunoterapie v současné době představují checkpoint inhibitory, kam patří CTLA-4 inhibitory (ipilimumab a tremelimumab) a PD-1/ PD-L1 inhibitory (nivolumab, pembrolizumab, durvalumab a avelumab). Mimo monoterapie jsou zkoumány i jejich různé kombinace nebo kombinace s chemoterapií nebo cílenou léčbou. Protinádorové vakcíny ani cytokiny nenalezly v léčbě plicního karcinomu větší význam, přesto, že zde byly zkoumány. Checkpoint inhibitory ukazují příznivé výsledky zejména v léčbě pa cientů s pokročilým stadiem (stadium IIIB a IV) nemalobuněčného karcinomu plic (non-small cell lung carcinoma -NSCLC) a jsou intenzivně zkoumány i u pa cientů s malobuněčným karcinomem plic (small cell lung carcinoma -SCLC). Cíl: Cílem této přehledové práce bylo sumarizovat nejvýznamnější dosažené poznatky o výsledcích, možnostech a perspektivách moderní imunoterapie v léčbě pa cientů s karcinomem plic. Závěr: Imunoterapie představuje významný směr moderní onkologické léčby a pro pa cienty s plicním karcinomem přináší naději na prodloužení života a zlepšení jeho kvality. Klíčová slova imunoterapie -karcinom plic -NSCLC -SCLC -checkpoint inhibitory AbstractBackground: Lung cancer occupies the leading position of cancer incidence and mortality worldwide, including in the Czech Republic. Despite significant advances in systemic oncology treatments, lung cancer still has the worst prognosis, which is driving the need for innovative therapies and methods to treat this disease. Immunotherapy is a developing area of systemic oncology treatment, which has recently begun to be significantly applied to patients with lung carcinoma. The most useful type of immunotherapy currently employs checkpoint inhibitors, including CTLA-4 inhibitors (ipilimumab and tremelimumab) and PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, durvalumab, and avelumab). Except for monotherapy, different combinations of these inhibitors or combinations between one more of these inhibitors and chemotherapy or targeted treatment are being actively studied. Despite intensive investigations, anti-tumor vaccines and cytokines have not had an important impact on the treatment of lung cancer. Checkpoint inhibitors have yielded favorable results, especially for the treatment of advanced (i.e., stage IIIB and IV) non-small cell lung cancer (NSCLC) and are being extensively investig...

show abstract

Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial

Cited by 25 publications

References 54 publications

The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis

The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis

Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting

Immunotherapy in the Treatment of Lung Cancer

Contact Info

Product

Resources

About